![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SCHERING-PLOUGH EXPANDS PRESENCE IN ASIA PACIFIC
SCHERING-PLOUGH EXPANDS PRESENCE IN ASIA PACIFIC
July 7, 2005
Schering-Plough Corporation today announced that it has opened commercial operations in Korea and Pakistan, effective July 1, 2005. The actions are part of a long-term strategy to build strength in its Asia Pacific region. Schering-Plough Korea is now headquartered in the capital city of Seoul. The company will assume responsibility for specialty care products, including Peg-Intron (peginterferon alfa-2b), Remicade (infliximab) and Temodal (temozolomide) as well as certain animal health products.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20524520&full=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct